Melanoma as a model for precision medicine in oncology

[1] Multisite Analytic Performance Studies of a Real-Time Polymerase Chain Reaction Assay for the Detection of BRAF V600E Mutations in Formalin-Fixed, Paraffin-Embedded Tissue Specimens of Malignant Melanoma [J]. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (11) : 1385 - 1391

[2] [Anonymous], N ENGL J MED

[3] Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway [J]. PLOS ONE, 2011, 6 (12):

[4] Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) : 2507 - 2516

[5] Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance [J]. NATURE, 2013, 494 (7436) : 251 - 255

[6] Mutations of the BRAF gene in human cancer [J]. NATURE, 2002, 417 (6892) : 949 - 954

[7] BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes [J]. PLOS ONE, 2011, 6 (10):

[8] Tumor adaptation and resistance to RAF inhibitors [J]. NATURE MEDICINE, 2013, 19 (11) : 1401 - 1409

[9] Long GV, 2012, LANCET ONCOL

[10] Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study [J]. LANCET ONCOLOGY, 2014, 15 (03) : 323 - 332

[1] Multisite Analytic Performance Studies of a Real-Time Polymerase Chain Reaction Assay for the Detection of BRAF V600E Mutations in Formalin-Fixed, Paraffin-Embedded Tissue Specimens of Malignant Melanoma [J]. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (11) : 1385 - 1391

[2] [Anonymous], N ENGL J MED

[3] Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway [J]. PLOS ONE, 2011, 6 (12):

[4] Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) : 2507 - 2516

[5] Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance [J]. NATURE, 2013, 494 (7436) : 251 - 255

[6] Mutations of the BRAF gene in human cancer [J]. NATURE, 2002, 417 (6892) : 949 - 954

[7] BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes [J]. PLOS ONE, 2011, 6 (10):

[8] Tumor adaptation and resistance to RAF inhibitors [J]. NATURE MEDICINE, 2013, 19 (11) : 1401 - 1409

[9] Long GV, 2012, LANCET ONCOL

[10] Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study [J]. LANCET ONCOLOGY, 2014, 15 (03) : 323 - 332